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Abstract
Inflammasomes monitor the cytosol for microbial contamination or perturbation, and are thus 
predicted to provide potent defense against infection. However, the compendium of data from 
murine infection models suggests that inflammasomes merely delay the course of disease, 
allowing the host time to mount an adaptive response. Interpretations of such results are 
confounded by inflammasome evasion strategies of vertebrate-adapted pathogens. Conversely, 
environmental opportunistic pathogens have not evolved in the context of inflammasomes, and are 
therefore less likely to evade them. Indeed, opportunistic pathogens do not normally cause disease 
in wild type animals. Accordantly, the extreme virulence of two opportunistic bacterial pathogens, 
Burkholderia thailandensis and Chromobacterium violaceum, is fully counteracted by 
inflammasomes in murine models. This leads us to propose a new hypothesis: perhaps animals 
maintain inflammasomes over evolutionary time not to defend against vertebrate-adapted 
pathogens, but instead to counteract infection by a plethora of undiscovered opportunistic 
pathogens residing in the environment.
Introduction
Sensors in the innate immune system survey either the extracellular/vacuolar space or the 
cytosol. Toll-like receptors (TLRs) and C-type lectin receptors survey the extracellular/
vacuolar compartment. In contrast, RIG-I-like receptors (RLRs), Nod-like receptors (NLRs), 
AIM2-like receptors (ALRs), and certain TRIM family proteins survey the cytosolic space. 
Amongst these cytosolic sensors, the canonical inflammasomes activate caspase-1. The 
exception to this paradigm of upstream sensors activating downstream signaling molecules 
is the so called “noncanonical inflammasome” pathway, in which murine caspase-11 (and its 
human orthologs caspase-4 and -5) have the cytosolic sensor and effector functions built into 
the same protein (1–2).
Caspase-1 activation leads to processing and secretion of the inflammatory cytokines IL-1β 
and IL-18, and also to a form of programmed lytic cell death called pyroptosis. 
Inflammasomes detect a wide range of cytosolic contaminants. AIM2 detects cytosolic 
DNA(3). NLRP3 responds to diverse stimuli that seem to trigger catastrophic cellular 
events(3). In a relatively unique mechanism, NLRC4 is activated by an upstream helper 
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NLR in the NAIP family that is the direct sensor for one of three bacterial proteins: T3SS 
rod, T3SS needle, or flagellin. These components aberrantly enter the host cytosol through 
the T3SS, presumably while the bacteria is injecting effector proteins to alter host cell 
function(s) (4). NLRP1b in the mouse responds to the anthrax lethal toxin by serving as a 
“lure” for this pathogen protease (5). Finally, Pyrin (also called TRIM20) senses 
perturbation of Rho GTPases by bacterial toxins (6). In contrast to these canonical 
inflammasomes, caspase-11/4/5 detect cytosolic LPS by direct interaction between LPS and 
their CARD domains (2). These noncanonical inflammasomes trigger pyroptosis, but do not 
process IL-1β directly.
Inflammasomes are evolutionarily maintained in vertebrates (7), although the repertoire may 
be expanded or contracted in various species. Inflammasomes are proposed to aid in defense 
against a variety of infections. However, inflammasome activation can also drive septic 
shock, leading to death (8, 9). This would exert a selective pressure to lose inflammasomes. 
With this in mind, does the current published evidence support a positive selective pressure 
that explains the maintenance of inflammasomes over evolutionary time?
In vivo data suggests that inflammasomes delay, but do not eradicate infection
In considering the positive selective pressure to maintain inflammasomes in defense against 
infection, many infectious studies have been performed using knockout mice, typically on 
the C57BL/6 background. Although inflammasome-deficient mice have increased 
susceptibility to many pathogens, the effect of inflammasomes on experimental survival 
studies is typically incremental. Salmonella enterica serovar Typhimurium (S. typhimurium) 
was one of the best and earliest examples. S. typhimurium replicates somewhat faster in 
Casp1−/−Casp11−/− mice, resulting in significantly increased burdens at any given time 
point post infection; for example at day 5 post infection, Casp1−/−Casp11−/− mice have 10 
fold higher burdens than wild type (WT) mice (10). This translates into the WT mice 
surviving two days longer than the Casp1−/−Casp11−/− mice (11), however it is important to 
remember that the WT mice still succumb, and thus the ultimate outcome of the infection 
remained unchanged. Our interpretation of these results is that inflammasomes alone cannot 
eradicate S. typhimurium, but merely slow its kinetics, which could be beneficial in that the 
animal may survive long enough to develop an adaptive immune response. In further 
support of this hypothesis, mice infected with Listeria monocytogenes that survive to days 
7–8 post infection are able to mount a cytotoxic T lymphocyte (CTL) response that will 
combat and clear the infection. It is well established that this CTL response will eliminate L. 
monocytogenes (12). Therefore, slowing the course of infection could be the positive 
selective pressure that maintains inflammasomes over evolutionary time.
Conversely, some infectious studies would, at first glance, suggest that inflammasomes have 
a critical role in defense. For example, we published that B. pseudomallei is lethal in 
Casp1−/−Casp11−/− mice, while WT mice survive the infection (13). On its surface, such a 
result seems to have incredible power, leading to the interpretation that inflammasomes fully 
prevent lethal infection. However, interpretation of this result is confounded by the fact that 
we chose the dose specifically because it was not lethal in WT mice; in other words, we 
defined the dose as being sublethal. When a deeper analysis of the dose response is 
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performed, the results lead to a more nuanced interpretation. In this regard, Fabio Re’s group 
examined three doses of B. pseudomallei infection. They demonstrated that as few as 25 
CFU resulted in 100% lethality in Casp1−/−Casp11−/− mice, whereas all the WT mice 
survive, consistent with our results. However, when Re’s group increased the dose, they 
found that 100 CFU caused an intermediate lethality in WT mice, and 200 CFU was 
sufficient to cause 100% lethality in WT mice (14). Therefore, inflammasome detection of 
B. pseudomallei resulted in approximately an 8-fold shift in the lethal infectious dose. While 
this is not an insignificant degree of protection, the general conclusion could be that both 
WT and Casp1−/−Casp11−/− mice succumb to extremely low dose B. pseudomallei 
challenge. Thus, our interpretation is that although experiments performed at doses just 
under the lethal dose can appear fully penetrant, they may actually reflect a more subtle 
phenotype.
We next considered whether this interpretation is consistent with other published data in 
infectious models. In contrast to Re’s work (14), most studies only use one infectious dose. 
Although this limits our ability to precisely evaluate the shift in lethal dose, we can estimate 
the minimum change supported by the data (rubric is described in Table 1 legend). As we 
wished to contrast various infectious models, we realized the difficulty of comparing 
pathogen burdens, pathology, or cytokine responses at various time points. On the other 
hand, the lethal challenge provides the same readout (survival) for an array of pathogens, 
routes, and doses; the survival assay also integrates temporal effects. We therefore attempted 
to identify and collate all lethal challenge studies that have been performed in 
inflammasome knockout mice in order to illustrate the relative importance of 
inflammasomes in defense against numerous pathogens (Table 1). Unless otherwise 
indicated (Table 1, Notes column), all KO mice in Table 1 are Casp1−/−Casp11−/− mice. It 
should be noted that while many survival studies have been performed with bacteria, fewer 
have been published with viral, fungal, and parasitic infection (further discussed below) 
(15–18). After collation of published survival studies (Table 1), it was striking that most 
changes in lethal dose were estimated to be in the 1–5 fold range.
Therefore, the combined results of all infection survival studies in inflammasome-deficient 
mice supports our interpretation that inflammasomes delay the course of infection, but do 
not have a dominant role in defense. Conversely, what if inflammasomes could provide 
rapid and potent defense against infection? This would exert a strong selective pressure for 
pathogens to evolve inflammasome evasion strategies, minimizing the utility of 
inflammasomes. The difference between these two interpretations has a profound influence 
on how we think about the importance of inflammasomes.
Vertebrate adapted pathogens evade inflammasomes
Indeed, many pathogens evade inflammasome detection. For example, S. typhimurium 
induces rapid and profound caspase-1 activation in vitro. However, S. typhimurium encodes 
two T3SSs (SPI-1 and SPI-2), of which only SPI-1 is detected by NLRC4. Therefore, upon 
host cell entry and during the systemic phase of infection in vivo, S. typhimurium suppresses 
SPI-1 expression in favor of the “silent” SPI-2 system. Further, S. typhimurium represses 
flagellin expression (19). The significance of these strategies in vivo cannot be understated, 
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since S. typhimurium engineered to express flagellin or SPI1 rod protein during systemic 
infection are completely attenuated in WT mice but fully virulent in inflammasome-deficient 
mice (4, 20). L. monocytogenes also represses flagellin, and is attenuated when engineered 
to persistently express it (21, 22). By virtue of being a Gram-positive bacterium, L. 
monocytogenes also naturally evades caspase-11, simply because it lacks LPS. On the other 
hand, cytosol-invasive Francisella species have evolved to actively modify their LPS 
structure to evade caspase-11 detection (9). Another mechanism to evade cytosolic LPS 
detection by caspase-11 is by replicating in the vacuole, as is the case with numerous 
vacuolar pathogens, including S. typhimurium (13).
In contrast, Yersinia species encode the effector YopM, which is capable of inhibiting 
caspase-1 by directly binding to the active site. This is critically important in vivo, as Y. 
pseudotuberculosis yopM mutants are attenuated in WT mice, but retain full virulence in 
Casp1−/−Casp11−/− mice (23). Similarly, Shigella flexneri encode the OspC3 T3SS effector 
that inhibits human caspase-4 (24), thus preventing detection of its LPS as the bacterium 
invades the cytosol. Direct inhibition of inflammasome components is not limited to 
bacteria. Indeed, poxviruses encode crmA, a serpin that can inhibit several caspases (both 
inflammatory and apoptotic) and was identified as a caspase-1 inhibitor before the discovery 
of pyroptosis (25). Further, Kaposi’s sarcoma-associated herpesvirus (KSHV) encodes an 
NLR analog (the tegument protein Orf63) that inhibits NLRP1 and NLRP3 activation of 
caspase-1 (26).
Another possible strategy for pathogens to cope with inflammasomes is to avoid the 
consequences downstream of inflammasome detection. B. pseudomallei may be an example 
of this strategy by resisting the neutrophil killing (27) that occurs after the bacteria are 
ejected into the extracellular space by pyroptosis (4). Staphylococcus aureus may be another 
example, as they are highly resistant to killing by neutrophils and have numerous toxins that 
inhibit neutrophil chemotaxis (28).
These pathogens are striking examples that demonstrate the importance of evading 
inflammasome detection (Figure 1). They show that inflammasomes could provide 
extremely potent defense against infection in vivo, but fail to do so because many pathogens 
minimize detection.
Inflammasomes defend against opportunistic pathogens
Vertebrate-adapted pathogens have evolved in the context of selective pressure exerted by 
the host immune system, and have accordingly potent virulence traits. In contrast, for 
opportunistic pathogens where humans are dead-end accidental hosts, there is no selective 
pressure to evade the human immune response. However, such microbes could also encode 
an impressive array of virulence factors, which can enable extreme pathogenicity. For 
example, B. thailandensis encodes cytosol-invasive T3SS, but almost never causes infection 
in people (29). As such, it has been used as an experimental surrogate for its close relative B. 
pseudomallei (a BSL3 pathogen); in this capacity, our laboratory has studied B. 
thailandensis infection in vivo in mice.
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Shockingly, during systemic infection with B. thailandensis there is a 1,000,000-fold change 
between Casp1−/−Casp11−/− and WT mice (Table 1). The resistance conferred by 
inflammasomes is extremely efficient; WT mice fully sterilize even high dose B. 
thailandensis infection (2×107 CFU) within just one day (29). Clearly, inflammasomes can 
provide potent protection when presented with this specific pathogen. The strength of this 
phenotype was extremely surprising, rivaled only by the effect of inflammasomes upon 
pathogens that were engineered to remove inflammasome evasion strategies. This made us 
re-evaluate the nature of B. thailandensis; we had simplistically considered it to be a 
surrogate for B. pseudomallei. However, it is important to keep in mind that B. thailandensis 
occupies a specific environmental niche as a soil microbe, where its T3SS is presumably 
used to invade the cytosol of an unknown eukaryotic host (30).
Is B. thailandensis an isolated unique case? With these thoughts in mind, we began to screen 
for other environmental opportunistic pathogens that primarily cause disease in 
immunocompromised individuals, hypothesizing that healthy individuals would competently 
clear them via the activity of inflammasomes.
In this endeavor, we discovered another ubiquitous environmental opportunistic pathogen 
against which inflammasomes play a similarly striking role, conferring a greater than 50,000 
fold shift in the lethal dose (Table 1). Chromobacterium violaceum is a Gram-negative 
bacterium that lives in the sediment of fresh-water rivers and lakes. Although C. violaceum 
encodes two T3SSs that are similar to Salmonella SPI-1 and SPI-2 and can be detected by 
NLRC4 (31), it virtually never causes disease in immunocompetent people (32).
A confounding factor in the identification of these examples is that there may be redundant 
host defense pathways that independently confer sterilizing innate immunity. Indeed, it is 
quite surprising that defense against C. violaceum and B. thailandensis is mono-allellic. 
However, our studies with C. violaceum did reveal that pyroptosis is partially redundant 
with natural killer (NK) cell cytotoxicity, although both are dependent on caspase-1 
activation (33). Further, if an opportunistic pathogen does not kill the host within one week, 
the adaptive immune response could compensate for the loss of inflammasomes.
Specific virulence traits are required for inflammasome detection and defense
As evidenced by the vertebrate-adapted column in Table 1, several opportunistic pathogens 
have been examined in Casp1−/−Casp11−/− mice, yet none have demonstrated such large 
changes in the lethal dose as seen with C. violaceum and B. thailandensis. C. violaceum 
encodes two T3SSs (34), and concomitantly, defense is conferred by NLRC4 in vivo (33). 
B. thailandensis invades the host cytosol, and its LPS is detected by caspase-11 (13, 29), 
which confers defense in vivo. In both cases, it is the specific virulence traits that are 
detected by the inflammasomes. The evasion strategies employed by vertebrate-adapted 
pathogens are likely not present in these environmental bacteria, as they did not evolve in 
the presence of potential inflammasome detection. For example, both Klebsiella pneumoniae 
and Vibrio vulnificus are opportunistic pathogens that typically cause disease in 
immunocompromised patients (35, 36), which fits our model that healthy individuals would 
be protected by inflammasomes. However, neither has a strong in vivo phenotype in 
inflammasome-deficient mice (Table 1). Additionally, neither encode a T3SS nor are 
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cytosol-invasive, as is the case for B. thailandensis and C. violaceum. Thus, they may lack 
inflammasome agonists.
Hypothesis
The predominance of evidence suggests that vertebrate-adapted pathogens have evolved to 
minimize the effectiveness of inflammasomes; in vivo phenotypes are typically incremental, 
and evasion strategies are prevalent. Why, then, are inflammasomes maintained in the 
human genome? The extreme virulence of B. thailandensis and C. violaceum in 
inflammasome-deficient mice leads us to propose a new hypothesis regarding the 
importance of inflammasomes in the immune system. We hypothesize that inflammasomes 
defend against ubiquitous environmental microbes with specific virulence traits. Further, we 
propose that inflammasome-directed defense is so efficient that the infection never 
progresses to clinically apparent symptoms. It is interesting to note that inflammasome-
deficient patients have not been identified. We speculate that a survey of apparently 
immunocompetent people with susceptibility to specific opportunistic pathogens, such as C. 
violaceum, could identify patients with inflammasome mutations. For example, in a case 
series of 106 C. violaceum infections, only 15 percent were directly attributed to an 
immunocompromising comorbidity (such as chronic granulomatous disease) (32).
Caveats to the hypothesis
There are several caveats that temper interpretation of the extreme virulence of B. 
thailandensis and C. violaceum in Casp1−/−Casp11−/− mice. One consideration is that 
Casp1−/−Casp11−/− animals are inbred and typically maintained on a C57BL/6 background 
that naturally lacks NRAMP1 (37). Mice lacking NRAMP1 have increased susceptibility to 
numerous intracellular pathogens, including S. typhimurium, L. monocytogenes, and 
Mycobacterium tuberculosis. This caveat has not gone unnoticed. In 2006, Lara-Tejero et al 
investigated the roles of inflammasomes in Nramp1-sufficient mice during S. typhimurium 
infection. However, regardless of the presence of a functional Nramp1 gene, 
Casp1−/−Casp11−/− mice still showed an incremental susceptibility to S. typhimurium 
infection in comparison to their WT counterparts (10).
Further, 129/SvEv mice are Nramp1-sufficient, but carry a spontaneous mutation in 
caspase-11 (38). Aachoui et al infected 129/SvEv (Casp11−/−Nramp1+/+) mice and found 
that they have extreme susceptibility to B. thailandensis that is comparable to C57BL/6 
Casp11−/− (Nramp1−/−) mice, whereas BALB/c (Casp11+/+Nramp1−/−) remained resistant 
(29). Thus, the potency of inflammasome defense against this environmental bacterium was 
not significantly altered by the presence or absence of Nramp1.
In addition to the influence of Nramp1 on different inbred mouse strains, there is also the 
fact that mice are not men; while this may seem to be an obvious caveat, it is one worth 
expanding upon. There are species barriers that can influence the virulence of pathogens. 
There are several examples of bacteria (Shigella spp, Salmonella typhi) that fail to establish 
mouse infections despite infectivity in humans. However, there are far more examples of 
viruses that have human-specific strains that do not infect mice: human cytomegalovirus, 
HIV, HBV, HCV, Epstein-Barr virus, measles, mumps, and many more (39). Therefore, 
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there could be more stringent non-inflammasome barriers restricting interspecies 
dissemination of viruses in comparison to bacteria. Therefore, our hypothesis that 
inflammasomes defend against environmental microbes might not hold true for viruses.
Certain inflammasomes, but not all, are conserved between mice and humans. NLRC4, 
NLRP3, caspase-1, and AIM2 are highly conserved over evolutionary time, from sharks to 
humans (Maltez and Miao BLAST searches). Yet, despite the high conservation of the ALR 
family member AIM2, there are 12 additional ALRs in mice but only 3 more in humans, 
suggesting active evolution of this gene family (40). Because AIM2/ALRs are often 
attributed to recognizing viral infections, the diversity within this family over evolutionary 
time could argue against the hypothesis that they defend against specific environmental 
pathogens. Similarly, mice encode three NLRP1 genes that are highly polymorphic between 
inbred mouse strains, and there is only one human NLRP1 (5). This again suggests active 
evolution of the NLRP1 locus. Thus, our hypothesis might only hold true for certain highly 
conserved inflammasomes, and not for the more divergent or polymorphic inflammasomes.
Conclusion
If vertebrate-adapted pathogens minimize the effectiveness of inflammasomes, why should 
we continue to study them? First, even sub-optimal inflammasome responses may have 
clinically beneficial effects during infection by vertebrate-adapted pathogens. Second, 
inflammasomes seem to be important drivers of the pathology of severe sepsis and septic 
shock (8, 9, 41). There are no immunologically directed therapies for sepsis; supportive 
treatments are useful, but nevertheless 28% of patients with sepsis die. Study of the 
downstream effect(s) of aberrant inflammasome activation could aid in the development of 
new directed treatments.
If vertebrate-adapted pathogens minimize the effectiveness of inflammasomes, how should 
we best study them? Opportunistic pathogens have the potential to lead us to novel insights 
and to reveal therapeutic approaches. Our work with C. violaceum demonstrates the reality 
of this potential – we discovered a novel link between inflammasome activation and in vivo 
perforin-mediated defense that was then applicable to L. monocytogenes infection as a 
cytokine therapy (33). With the rise in antibiotic-resistant microbes, there is a pressing need 
for new immunotherapeutic approaches to treat infection.
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Figure 1. Inflammasomes readily detect opportunistic microbes while vertebrate-adapted 
pathogens evade
Numerous pathogens evade inflammasome detection by repression or modification of 
ligands (yellow arrows) or by direct inhibition with specific virulence factors (red arrows). 
Concomitantly, the beneficial effect of inflammasomes against such pathogens is typically 
blunted in vivo (see Table 1). In contrast, two environmental bacteria (Chromobacterium 
violaceum and Burkholderia thailandensis) are potently detected by inflammasomes (green 
arrows), and inflammasome defense in vivo is accordingly robust. Thus, we hypothesize that 
inflammasomes defend against environmental pathogens with specific virulence traits and 
may have limited utility against vertebrate-adapted bacterial pathogens, which have evolved 
to evade and/or inhibit them.
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